fondaparinux sodium

fondaparinux sodium (ARIXTRA) is an FDA-listed pharmaceutical active ingredient. Associated with BRIGHT MINDS BIOSCIENCES INC.. Route of administration: subcutaneous. Current US regulatory status: approved.

ARIXTRA is a marketed brand name for fondaparinux sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

fondaparinux sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.